Mar, 2019

U.S.A.
News / Corporate
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the first cohort of...
Read More
U.S.A.
News / Corporate
Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients
Astellas announced today that PROGRAF® Granules (tacrolimus for oral suspension) is now available for prescription in the United States. PROGRAF is used in combination with other...
Read More

Feb, 2019

U.S.A.
News / Corporate
Astellas and WiserCare Announce Collaboration to Improve Patient Experience
Astellas US LLC and WiserCare, a company that develops healthcare decision support solutions, announced today a new collaboration focused on improving patient experience by eliciting and...
Read More
U.S.A.
News / Corporate
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today results from the Phase 3 ARCHES trial in men with metastatic...
Read More

Dec, 2018

U.S.A.
News / Corporate
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide)...
Read More